Compare First Citizens BancShares Inc (FCNCA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Johnson & Johnson — how do they compare? First Citizens BancShares Inc trades at $2,064.45 (market cap $22.94B), while Johnson & Johnson trades at $259.54 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 26.9× First Citizens BancShares Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 29 Days and Johnson & Johnson for 129 Days on average.
| FCNCA | JNJ | |
|---|---|---|
Market Cap | $22.94B | $618.09B |
Volume | 91,668 | 6,050,983 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $278.43 |
52-Week Low | $1.64K | $186.00 |
Typical Hold Time | 29 Days | 129 Days |
Dividend Yield | 0.41% | 2.09% |
Enterprise Value | — | $646.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,071.56, down 0.79% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with a P/E of 11.11 and net income margin of 25.23%, and has beaten EPS estimates for the last three quarters. Recent corporate actions include a $2.10 dividend and expansion through branch acquisitions and new financing initiatives.
The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but near-term technical weakness and high institutional hold ratings suggest caution. Key risks include execution of growth initiatives and broader economic pressures on banking.
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
